Freeline Therapeutics Holdings plc (FRLN)

0.7360 -0.0083 (-1.12%) At close: 04:00PM EDT

Freeline Therapeutics Holdings plc

Stevenage Bioscience Catalyst
Gunnels Wood Road
Stevenage SG1 2FX
United Kingdom
44 14 3890 6870
https://www.freeline.life

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 235

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Michael J. Parini J.D.	CEO, COO, Pres & Exec. Director	1.13M	N/A	1975
Dr. Amit Chunilal Nathwani M.D., Ph.D.	Founder, Independent Clinical & Scientific Advisor and Director	513k	N/A	1960
Dr. Markus Horer Ph.D.	Founder, CTO & Managing Director GmbH	N/A	N/A	1967
Mr. Stephen P. Diamond Jr.	Sr. VP, Gen. Counsel & Company Sec.	N/A	N/A	1972
Mr. Mark Baldry M.B.A.	Chief Commercial Officer	N/A	N/A	1964
Mr. James Bircher	Chief Technical Operations Officer	N/A	N/A	1969
Dr. Pamela Foulds M.D.	Chief Medical Officer	N/A	N/A	1970
Ms. Amy J. Spandau	Interim Head of Fin.	N/A	N/A	1976
Dr. Henning R. Stennicke Ph.D.	Chief Scientific Officer	N/A	N/A	1968
Arne Naeveke Ph.D.	VP & Head of Corp. Communications	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Corporate governance

Freeline Therapeutics Holdings plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.